SNSumi Nandwani

Sumi Nandwani

*This is an algorithmically generated author record based on publicly available information.

Sumi Nandwani has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sepsis and Liver Abscess Caused by Leuconostoc mesenteroides in a Pediatric Patient with Aplastic Anemia

    by Pravesh Kumar, Eby P Baby, Hari Gaire, Anuj Singh, Silky Jain, Sumi Nandwani, Deeksha Bhalla, Nita Radhakrishnan

    Aplastic anemia is a potentially life-threatening condition characterized by bone marrow failure, leading to severe pancytopenia and an increased risk of bacterial and fungal infections. The management of such infections is challenging in immunocompromised patients, particularly in the absence of definitive guidelines. We report a case of a 10-year-old boy with very severe aplastic anemia who developed sepsis and a liver abscess due to Leuconostoc mesenteroides. The infection resolved only after improvement of the absolute neutrophil count following hematopoietic stem cell transplantation. Because this organism is intrinsically resistant to vancomycin, treatment may require prolonged therapy with aminoglycosides, chloramphenicol, macrolides and other active agents. This case highlights the importance of considering rare pathogens such as L. mesenteroides in immunocompromised patients with persistent infections. Keywords: Leuconostoc mesenteroides, sepsis, liver abscess, severe aplastic anemia

  • Open Access

    Evaluation of Diagnostic Performance of Line Probe Assay on Smear-Negative Samples of Pulmonary Tuberculosis

    by Sumi Nandwani, Sanjay Singhal, Dipti Gothi, Ritu Singhal, Naz Perween, Kavita Gupta, Raunak Bir, Jayanthi Gunasekaran, Anushka Soni, Urmila Chaudhary

    Background: This study aims to compare the performance of line probe assay (LPA) on smear-negative samples with that of smear-positive samples for diagnosing pulmonary tuberculosis (PTB) and first-line drug sensitivity testing (FL DST).


  • Open Access

    Retrospective Analysis of Urinary Tract Infection in the Pediatric Population at a Tertiary Care Centre

    by Naz Perween, Sumit Rai, Sumi Nandwani, Shyam Kishor Kumar

    Background: Urinary tract infection (UTI) is among the most common infections occurring during childhood. It is caused by both gram-negative and gram-positive bacteria and Escherichia coli is the most common causative agent. Methods: Data of all pediatric patients in the age group of 6 months to 18 years with urinary tract infection were taken for analysis. Urine samples were collected and cultured on the cystine lactose electrolyte-deficient medium. The presence of bacteria was identified using biochemicals, and the antimicrobial test was performed using the Kirby-Bauer test or the VITEK 2 compact system (bioMérieux, Inc., France). Results: The prevalence of UTI was 23.5%. In total, 614 specimens tested positive with significant bacteriuria. The male-to-female ratio was 1:2.3. Approximately 54% patients presented with urinary symptoms alone. Culture positivity was significantly associated with pyuria (p < 0.0001). E. coli (334/614) was the most common isolate, followed by Enterococcus spp. (92/614). Colistin, polymyxin B, fosfomycin, nitrofurantoin, netilmicin, and amikacin were extremely good acting antimicrobials. Meanwhile, ampicillin, cefotaxime, ceftriaxone, and norfloxacin were highly resistant to gram-negative bacteria. Multidrug-resistant bacteria and extended-spectrum beta-lactamase-producing bacteria were found in 47% and 44.1% of cases, respectively. Vancomycin, linezolid, teicoplanin, and nitrofurantoin were highly effective against gram-positive bacteria. Furthermore, norfloxacin, trimethoprim/sulfamethoxazole, ciprofloxacin, and tetracycline were highly resistant to gram-positive bacteria. Of the 92, 42 Enterococcus spp. were resistant to high-dose gentamicin. Conclusion: Nitrofurantoin and amikacin can be used as empirical therapy for gram-negative and gram-positive bacteria. Because resistance to various commonly used antibiotics is found to be increasing, treatment must be guided by antibiotic susceptibility reports.